Box plots of the concentration levels for (A) metabolites and (B) lipoprotein parameters (main parameters, calculated figures and main fractions) that have a p-value < 0.05 and a large Cliff’s delta effect size in the comparison between mild, sever and fatal COVID-19 groups. The concentration levels in COVID-19-R subjects are also reported as control values. In each plot, the grey stripe embraces the concentration range in the reference “healthy” population. Colour coding: mild (light red); severe (red); fatal (dark red) COVID-19-R (yellow). * indicates p-value < 0.05: the upper line indicates the statistical significance between all the COVID-19 subjects and the COVID-19-R group; the lower lines indicate statistical significance between pa...
Values of Log2 fold change (FC) of quantified lipoprotein parameters (particle numbers and HDL, LDL,...
A. Heatmap and hierarchical clustering analysis of COVID-19 and control individuals with all the met...
A. Score plot of PLS-DA analysis of healthy controls (H), mild/moderate (M), and severe (S) patients...
Box plots of (A) metabolites and (B) lipoproteins concentration levels in COVID-19 positive subjects...
Box plots of (A) mannose and (B) glucose concentration levels in COVID-19 positive subjects grouped ...
(A) List of lipoprotein parameters (main parameters, calculated figures and main fractions) quantifi...
A) List of lipoprotein parameters (main parameters, calculated features and main fractions) quantifi...
(A) Main demographic and clinical characteristics of the enrolled subjects (right panel); for each g...
Box plots of the concentration levels for (A) metabolites and (B) lipoprotein parameters (main param...
(A) Proximity plots of the RF model discriminating COVID-19 patients (mild light red dots, severe re...
Box plots of Mannose, Glucose and Creatinine concentration levels in the 510 COVID-19 positive subje...
(A) Number of samples used for the analysis. (B-C) Values of Log2 fold change (FC) of quantified met...
(A) Main demographic and clinical characteristics of the subjects. (B-C) Values of Log2 fold change ...
Top down: the first row is corresponding to the number of infections in Alpha variant, the second ro...
Top down: the first row is corresponding to the number of infections in Alpha variant, the second ro...
Values of Log2 fold change (FC) of quantified lipoprotein parameters (particle numbers and HDL, LDL,...
A. Heatmap and hierarchical clustering analysis of COVID-19 and control individuals with all the met...
A. Score plot of PLS-DA analysis of healthy controls (H), mild/moderate (M), and severe (S) patients...
Box plots of (A) metabolites and (B) lipoproteins concentration levels in COVID-19 positive subjects...
Box plots of (A) mannose and (B) glucose concentration levels in COVID-19 positive subjects grouped ...
(A) List of lipoprotein parameters (main parameters, calculated figures and main fractions) quantifi...
A) List of lipoprotein parameters (main parameters, calculated features and main fractions) quantifi...
(A) Main demographic and clinical characteristics of the enrolled subjects (right panel); for each g...
Box plots of the concentration levels for (A) metabolites and (B) lipoprotein parameters (main param...
(A) Proximity plots of the RF model discriminating COVID-19 patients (mild light red dots, severe re...
Box plots of Mannose, Glucose and Creatinine concentration levels in the 510 COVID-19 positive subje...
(A) Number of samples used for the analysis. (B-C) Values of Log2 fold change (FC) of quantified met...
(A) Main demographic and clinical characteristics of the subjects. (B-C) Values of Log2 fold change ...
Top down: the first row is corresponding to the number of infections in Alpha variant, the second ro...
Top down: the first row is corresponding to the number of infections in Alpha variant, the second ro...
Values of Log2 fold change (FC) of quantified lipoprotein parameters (particle numbers and HDL, LDL,...
A. Heatmap and hierarchical clustering analysis of COVID-19 and control individuals with all the met...
A. Score plot of PLS-DA analysis of healthy controls (H), mild/moderate (M), and severe (S) patients...